茚烷-2-甲胺盐酸盐 | 146737-65-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 茚烷-2-甲胺盐酸盐
• 英文名称: (2,3-dihydro-1H-inden-2-yl)methanamine
• 英文别名: 2,3-dihydro-1H-inden-2-ylmethanamine
• CAS: 146737-65-7
• 化学式: C₁₀H₁₃N
• mdl: MFCD04114560
• 分子量: 147.22
• InChiKey: COWVOJUAZGKGRQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921499090

反应信息

• 作为反应物：
  描述：

  茚烷-2-甲胺盐酸盐 在 10percent Pd/C 吡啶 、 氢气 、 硝酸 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 20.0 ℃ 、344.75 kPa 条件下， 反应 20.5h， 生成 methyl N-[[5-[[2-(4-chlorophenyl)-3-methylbenzoyl]amino]-2,3-dihydro-1H-inden-2-yl]methyl]carbamate
  参考文献：
  名称：

  Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors

  摘要：

  The synthesis and biological activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compounds, 8aR, inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, respectively. In normolipidemic rats and dogs, oral administration of 8aR dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, 8aR also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low density lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by 8aR. However, hepatic lipid accumulation resulted in negligible change in total liver weight and was reversible after withdrawal of the compound.

  DOI：

  10.1021/jm010294e
• 作为产物：
  描述：

  2-茚醇 在 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 N,N-二异丙基乙胺 作用下， 以 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 茚烷-2-甲胺盐酸盐
  参考文献：
  名称：

  Diaminoindanes as Microsomal Triglyceride Transfer Protein Inhibitors

  摘要：

  The synthesis and biological activities of biarylamide-substituted diaminoindanes as microsomal triglyceride transfer protein (MTP) inhibitors are described. One of the more potent compounds, 8aR, inhibited both the secretion of apoB from Hep G2 cells and the MTP-mediated transfer of triglycerides between synthetic acceptor and donor liposomes with IC50 values of 0.7 and 70 nM, respectively. In normolipidemic rats and dogs, oral administration of 8aR dose-dependently reduced both plasma triglycerides and total cholesterol. Moreover, in rats and dogs, 8aR also prevented the postprandial rise in plasma triglycerides following a bolus administration of a fat load. Because MTP inhibitors decrease very low density lipoprotein assembly in the liver, the potential for hepatic lipid accumulation was evaluated. In normolipidemic rats, hepatic cholesterol and triglyceride contents were dose-dependently increased by 8aR. However, hepatic lipid accumulation resulted in negligible change in total liver weight and was reversible after withdrawal of the compound.

  DOI：

  10.1021/jm010294e

文献信息

• Nickel-Catalyzed Enantioselective α-Alkenylation of <i>N</i>-Sulfonyl Amines: Modular Access to Chiral α-Branched Amines
  作者：Lun Li、Yu-Cheng Liu、Hang Shi

  DOI：10.1021/jacs.1c00622

  日期：2021.3.24

  α-branched amines are common structural motifs in functional materials, pharmaceuticals, and chiral catalysts. Therefore, developing efficient methods for preparing compounds with these privileged scaffolds is an important endeavor in synthetic chemistry. Herein, we describe an atom-economical, modular method for a nickel-catalyzed enantioselective α-alkenylation of readily available linear N-sulfonyl amines

  手性α-支化胺是功能材料、药物和手性催化剂中常见的结构基序。因此，开发用于制备具有这些特权支架的化合物的有效方法是合成化学中的一项重要努力。在这里，我们描述了一种原子经济的模块化方法，用于镍催化的线性N 的对映选择性 α-烯基化-磺胺与炔烃可提供多种烯丙基胺，无需外源性氧化剂、还原剂或活化剂。该方法为构建手性α-支化胺以及α-氨基酰胺和β-氨基醇等衍生物提供了一个平台，这些衍生物可以方便地从新引入的烯烃中获得。鉴于该方法的通用性、多功能性和高原子经济性，我们预计它将具有广泛的合成效用。
• [EN] TACHYKININ RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES DU RECEPTEUR TACHYKININE
  申请人：LILLY CO ELI

  公开号：WO2005000821A1

  公开（公告）日：2005-01-06

  The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

  本发明涉及选择性NK-1受体拮抗剂的化学式(I)或其药用盐，用于治疗与过多的缓激肽相关的疾病。
• Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
  申请人：——

  公开号：US20030055071A1

  公开（公告）日：2003-03-20

  Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.

  描述了包括某些喹啉羧酰胺和萘啉羧酰胺衍生物在内的氮杂萘基羧酰胺衍生物。这些化合物是HIV整合酶的抑制剂和HIV复制的抑制剂，可用于预防或治疗HIV感染和治疗艾滋病，作为化合物或药学上可接受的盐，或作为药物组合物中的成分，可选择与其他抗病毒药物、免疫调节剂、抗生素或疫苗组合使用。还描述了预防、治疗或延缓艾滋病发作的方法，以及预防或治疗HIV感染的方法。
• Cyclic imino derivatives and pharmaceutical compositions containing them
  申请人：Karl Thomae GmbH

  公开号：US05541343A1

  公开（公告）日：1996-07-30

  The invention relates to cyclic imino compounds which have, inter alia, valuable pharmacological properties, especially inhibitory effects on cell aggregation, pharmaceutical compositions which contain these compounds and processes for preparing them.

  这项发明涉及具有有价值的药理特性，特别是对细胞聚集具有抑制作用的环亚胺化合物，包含这些化合物的药物组合物以及制备它们的方法。
• [EN] QUINOLINE-2-ONE-DERIVATIVES FOR THE TREATMENT OF AIRWAYS DISEASES<br/>[FR] DERIVES DE QUINOLINE-2-ONE PERMETTANT DE TRAITER DES MALADIES DES VOIES RESPIRATOIRES
  申请人：NOVARTIS AG

  公开号：WO2004087142A1

  公开（公告）日：2004-10-14

  Compounds of formula (I) in free or salt form, wherein -C-Y-, R1 and R2 are G have the meanings as indicated in the specification, are useful for treating conditions that are prevented or alleviated by activation of the (β2-adrenoreceptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  式(I)的化合物以自由形式或盐形式存在，其中-C-Y-，R1和R2是G，其含义如规范中所示，可用于治疗通过激活β2-肾上腺素受体预防或缓解的疾病。还描述了含有这些化合物的药物组合物以及制备这些化合物的方法。